S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
NASDAQ:XDNA

Kelly CRISPR & Gene Editing Technology ETF (XDNA) Price, Holdings, & News

$7.38
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$7.38
$7.38
50-Day Range
$7.38
$7.38
52-Week Range
$5.87
$11.83
Volume
N/A
Average Volume
3,034 shs
Market Capitalization
$2.21 million
Assets Under Management
$2.58 million
Dividend Yield
0.12%
Net Expense Ratio
0.78%
XDNA stock logo

About Kelly CRISPR & Gene Editing Technology ETF (NASDAQ:XDNA)

The Strategic CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly.

XDNA Stock Price History

XDNA ETF News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Gene editing is now a medical reality
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
See More Headlines
Receive XDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kelly CRISPR & Gene Editing Technology ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
Kelly Strategic Management
Fund Name
Kelly CRISPR & Gene Editing Technology ETF
Tax Classification
Regulated Investment Company
Current Symbol
NASDAQ:XDNA
Inception Date
1/12/2022
Fund Manager
Dustin Lewellyn, Ernesto Tong, Anand Desai
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
Strategic CRISPR & Gene Editing Technology Index
Category
Strategy
Focus
Theme
Development Level
Developed Markets
Region
Global
Number of Holdings
2

Fund Statistics

Assets Under Management
$2.58 million
Average Daily Volume
$0.00
Discount/Premium
0.00%

Administrator, Advisor and Custodian

Administrator
U.S. Bancorp Fund Services, LLC
Advisor
Kelly Strategic Management, LLC
Custodian
U.S. Bank, N.A.
Distributor
Foreside Fund Services, LLC
Transfer Agent
U.S. Bancorp Fund Services, LLC
Trustee
N/A
Lead Market Maker
Jane Street

Miscellaneous

Beta
0.92
Creation Unit
25,000
Creation Fee
$250.00
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Kelly CRISPR & Gene Editing Technology ETF Expenses

TypeXDNATheme ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.78%0.57%0.54%0.48%0.51%
Other Expenses0.00%0.71%0.54%0.32%0.58%
Total Expense0.78%0.72%0.70%0.57%0.70%
Fee Waiver0.00%-0.76%-0.54%-0.20%-0.56%
Net Expense0.78%0.59%0.60%0.54%0.58%

Kelly CRISPR & Gene Editing Technology ETF (XDNA) Holdings


XDNA ETF - Frequently Asked Questions

How have XDNA shares performed in 2024?

Kelly CRISPR & Gene Editing Technology ETF's stock was trading at $7.38 at the beginning of the year. Since then, XDNA stock has increased by 0.0% and is now trading at $7.38.
View the best growth stocks for 2024 here
.

What does XDNA invest in?

Kelly CRISPR & Gene Editing Technology ETF is a equity fund issued by Kelly Strategic Management. XDNA focuses on theme investments and follows the Strategic CRISPR & Gene Editing Technology Index. The fund's investments total to approximately $2.58 million assets under management.

What stocks does Kelly CRISPR & Gene Editing Technology ETF hold?
What is the management fee for Kelly CRISPR & Gene Editing Technology ETF?

Kelly CRISPR & Gene Editing Technology ETF's management fee is 0.78% and has no other recorded expenses or fee waivers. The net expense ratio for XDNA is 0.78%.

How do I buy shares of Kelly CRISPR & Gene Editing Technology ETF?

Shares of XDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XDNA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners